AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
AGIOS PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$34.90+3.58 (+11.43%)
Close on Oct 19, 2026
- Market cap
- $2.08B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$7.43 (−17.55%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
AGIOS PHARMACEUTICALS, INC. grew revenue 140.6% to $98.34M over the twelve months to Jun 30, 2026. Free cash flow was -$365.25M.
Revenue
$98.34M
+140.6% vs. a year earlier
Operating income
-$459.02M
TTM Q2 2026
Free cash flow
-$365.25M
TTM Q2 2026
EPS, diluted
-$7.01
-163.2% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.08B
- P/E ratio
- –
- Price to sales
- 21.11
- Price to book
- 2.02
- Dividend yield
- –
- Free cash flow yield
- -17.59%
Fundamentals
- Revenue
- $98.34M
- Net income
- -$411.29M
- EPS, diluted
- -$7.01
- Free cash flow
- -$365.25M
- Book value per share
- $17.25
- Diluted shares
- 59M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$98.34M+140.6% YoY
Gross profit
$90.47M+151.0% YoY
Operating income
-$459.02M
Net income
-$411.29M-163.3% YoY
EPS, diluted
-$7.01-163.2% YoY
Free cash flow
-$365.25M
Reported periodTrailing twelve months